Cover Image

First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration

<b>Background</b>: To evaluate the outcomes of intravitreal faricimab (IVF) for refractory neovascular age-related macular degeneration (nAMD) and investigate the impact of baseline optical coherence tomography, biomarkers for total IVF injections are needed. <b>Methods</b>:...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wissam Aljundi (Author), Loay Daas (Author), Shady Suffo (Author), Berthold Seitz (Author), Alaa Din Abdin (Author)
Format:	Book
Published:	MDPI AG, 2024-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022)

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
by: Lorenzo Ferro Desideri, et al.
Published: (2023)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021)

Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy
by: Nair AA, et al.
Published: (2022)

Evaluation of Aqueous Flare Intensity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular Age-Related Macular Degeneration
by: Joanna Dolar-Szczasny, et al.
Published: (2021)

Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
by: Jose Navarro-Partida, et al.
Published: (2021)

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab
by: Pablo Almuiña-Varela, et al.
Published: (2024)

The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2024)

EFEMP1 Overexpression Contributes to Neovascularization in Age-Related Macular Degeneration
by: Lu Cheng, et al.
Published: (2021)

Profile of conbercept in the treatment of neovascular age-related macular degeneration
by: Lu XM, et al.
Published: (2015)

Intravitreal Bevacizumab Injection Effect in Exudative Age Related Macular Degeneration
by: Gholamhossein Yaghoobi, et al.
Published: (2016)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2019)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
by: Wataru Kikushima, et al.
Published: (2023)

Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies
by: Panos GD, et al.
Published: (2023)

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
by: Jing Wang, et al.
Published: (2021)

Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
by: Pengxiang Zhou, et al.
Published: (2021)

Contextualizing single‐arm trials with real‐world data: An emulated target trial comparing therapies for neovascular age‐related macular degeneration
by: Darren S. Thomas, et al.
Published: (2021)

Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study
by: Ida Korva-Gurung, et al.
Published: (2023)

Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
by: Wang LP, et al.
Published: (2018)

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
by: Yang S, et al.
Published: (2016)

Identifying subtypes of patients with neovascular age-related macular degeneration by genotypic and cardiovascular risk characteristics
by: Kim Ivana K, et al.
Published: (2011)

Application of Artificial Intelligence Models to Predict the Onset or Recurrence of Neovascular Age-Related Macular Degeneration
by: Francesco Saverio Sorrentino, et al.
Published: (2024)

Polymorphic nanobody crystals as long‐acting intravitreal therapy for wet age‐related macular degeneration
by: Shuqian Zhu, et al.
Published: (2023)

Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration
by: Gebran Khneizer, et al.
Published: (2017)

Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: A systematic review, meta-analysis, and trial sequential analysis
by: Guanran Zhang, et al.
Published: (2024)

Hypertensive disorders of pregnancy increase the risk of developing neovascular age-related macular degeneration in later life
by: Karen Curtin, et al.
Published: (2019)

Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration
by: Hussain RM, et al.
Published: (2021)

Accidental intralenticular injection of dexametasone intravitreal implant during the treatment of refractory diabetic macular oedema
by: M. I. Kovtun, et al.
Published: (2018)

Health-related quality of life in patients with neovascular age-related macular degeneration: a prospective cohort study
by: Anna-Maria Kubin, et al.
Published: (2024)

Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
by: Yinchen Shen, et al.
Published: (2022)

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
by: Nadia Zakaria, et al.
Published: (2022)

Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration
by: Li W, et al.
Published: (2016)

The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration
by: A. F. Yusupov, et al.
Published: (2024)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
by: Nicola Ferrante, et al.
Published: (2022)

The influence of delayed treatment due to COVID-19 on patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
by: Xinyu Zhao, et al.
Published: (2021)

Molecular Biomarkers of Neovascular Age-Related Macular Degeneration With Incomplete Response to Anti-Vascular Endothelial Growth Factor Treatment
by: Irmela Mantel, et al.
Published: (2020)

Ocular Safety of Intravitreal Injections of Age-Related Macular Degeneration Treatments in a Prospective Observational Cohort Study in Europe
by: Kui Huang, et al.
Published: (2015)

Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis
by: Ba J, et al.
Published: (2015)

Mingjing granule inhibits the subretinal fibrovascular membrane of two-stage laser-induced neovascular age-related macular degeneration in rats
by: Xiaoyu Li, et al.
Published: (2024)